Table 3.

Twenty high-priced specialty drugs covered by Medicare Part D with fewer than 200,000 beneficiaries and less than 1 million claims filled in 2013

Generic name	Therapeutic class	Beneficiaries (N)	Claims (N)	Cost to Part D (in millions of US$)	Overall rank on Part D reimbursement list
1. Lenalidomide	Cancer	24,637	153,782	1350	10
2. Glatiramer acetate	Unclassified	27,424	224,167	1120	13
3. Etanercept	Arthritis	50,570	354,298	980	15
4. Adalimumab	Arthritis	46,448	325,242	960	16
5. Imatinib	Cancer	13,684	110,658	780	21
6. Sevelamer carbonate	Mineral supplement	184,164	939,717	730	22
7. Emtricitabine/tenofovir	Anti-infective	57,263	488,245	620	29
8. Cinacalcet hydrochloride	Unclassified	117,921	117,921	610	31
9. Quetiapine fumarate	Psychotherapeutic	143,622	999,405	540	35
10. Efavirenz/emtricitabine/tenofovir	Anti-infective	29,585	264,284	530	37
11. Abiraterone acetate	Cancer	14,191	71,423	470	43
12. Bosentan	Unclassified	7100	64,824	450	48
13. Paliperidone palmitate	Psychotherapeutic	38,061	303,094	420	52
14. Erlotinib hydrochloride	Cancer	14,237	71,058	400	54
15. Raltegravir potassium	Anti-infective	39,132	338,249	380	57
16. Interferon beta-1A	Unclassified	9983	80,328	370	60
17. Ambrisentan	Unclassified	6040	49,128	330	66
18. Darunavir ethanolate	Anti-infective	34,353	289,830	330	67
19. Interferon beta-1A albumin	N/A	7894	66,819	300	81
20. Everolimus	Cancer	7568	32,123	270	88

N/A Not Applicable